^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    1d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    2d
    A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    2d
    A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray (clinicaltrials.gov)
    P1, N=60, Recruiting, VivaVision Biotech, Inc
    New P1 trial
    6d
    ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355
    Phase classification • Enrollment change
    |
    mercaptopurine
    10d
    HEMA-MED: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, iOnctura | Initiation date: May 2025 --> Nov 2025
    Trial initiation date
    |
    Jakafi (ruxolitinib) • roginolisib (IOA-244)
    13d
    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome (clinicaltrials.gov)
    P2, N=56, Recruiting, Icahn School of Medicine at Mount Sinai
    New P2 trial
    15d
    XRPMS: Korean Post-marketing Surveillance for Xeljanz XR (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Pfizer | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR)
    24d
    A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) (clinicaltrials.gov)
    P2, N=160, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    25d
    Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=8, Terminated, M.D. Anderson Cancer Center | Trial completion date: May 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2027 --> Oct 2025; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    itacitinib (INCB039110)
    1m
    Clinical study of JAK inhibitors in the treatment of rosacea with erythematotelangiectatic rosacea (ChiCTR2500109214)
    P=N/A, N=84, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    tofacitinib
    1m
    Clinical characteristics of alopecia areata patients in the real world and long-term efficacy and safety of the new JAK inhibitor in the treatment of alopecia areata (ChiCTR2500107789)
    P4, N=337, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P4 trial • Real-world evidence
    1m
    IMpactMF: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment (clinicaltrials.gov)
    P3, N=320, Active, not recruiting, Geron Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    hydroxyurea • Rytelo (imetelstat)